A Study of GFH925 in Patients With Advanced Solid Tumors With KRAS G12C Mutations

  • End date
    Apr 10, 2024
  • participants needed
  • sponsor
    Zhejiang Genfleet Therapeutics Co., Ltd.
Updated on 4 October 2022


Phase I: To evaluate the safety and tolerability of GFH925 in subjects with KRAS G12C mutant advanced solid tumors and estimate the maximum tolerated dose (MTD) and/or a recommended phase 2 dose (RP2D).Phase II: To evaluate the efficacy of GFH925 in subjects with KRAS G12C mutant advanced non-small cell lung cancer (NSCLC).

Condition KRAS G12C
Treatment GFH925
Clinical Study IdentifierNCT05005234
SponsorZhejiang Genfleet Therapeutics Co., Ltd.
Last Modified on4 October 2022


Yes No Not Sure

Inclusion Criteria

Men or women ≥18 years old
Pathologically diagnosed, previously treated, advanced tumor with KRAS p.G12C mutation
Adequate organ function
Measurable disease per RECIST 1.1 criteria

Exclusion Criteria

Significant concomitant diseases
Active brain metastases
Previous treatment with KRAS G12C inhibitor
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note